R Squared’s Moderna MRNA Stock Holding History

R Squared’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$395K	Buy	+5,647	New	+$292K	0.21%	147
2025 Q1	–	Sell	-110	Closed	-$4.57K	–	1026
2024 Q4	$4.57K	Buy	+110	New	+$5.26K	﹤0.01%	1332

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

R Squared's MRNA Position: Q2 2026 in Review

R Squared opened a new position in Moderna (MRNA) in Q2 2026: 5,647 shares worth $395K. The stake represents 0.21% of the portfolio and ranks #147 among its holdings. This is a return to the name: R Squared previously reported a position in MRNA as recently as Q4 2024.

R Squared first reported a position in MRNA in Q4 2024 and has held it in 2 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

R Squared held 5,647 shares of Moderna worth $395K as of Q2 2026.
Moderna was a new R Squared position in Q2 2026.
Moderna made up 0.21% of R Squared's portfolio in Q2 2026, its #147 holding.
R Squared first reported a position in Moderna in Q4 2024 and has held it in 2 quarters since.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.